196 related articles for article (PubMed ID: 21314952)
1. Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines.
Eng L; Ibrahim-zada I; Jarjanazi H; Savas S; Meschian M; Pritchard KI; Ozcelik H
BMC Med Genomics; 2011 Feb; 4():18. PubMed ID: 21314952
[TBL] [Abstract][Full Text] [Related]
2. A whole-genome SNP association study of NCI60 cell line panel indicates a role of Ca2+ signaling in selenium resistance.
Savas S; Briollais L; Ibrahim-zada I; Jarjanazi H; Choi YH; Musquera M; Fleshner N; Venkateswaran V; Ozcelik H
PLoS One; 2010 Sep; 5(9):e12601. PubMed ID: 20830292
[TBL] [Abstract][Full Text] [Related]
3. Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.
Leandro-García LJ; Leskelä S; Jara C; Gréen H; Avall-Lundqvist E; Wheeler HE; Dolan ME; Inglada-Perez L; Maliszewska A; de Cubas AA; Comino-Méndez I; Mancikova V; Cascón A; Robledo M; Rodríguez-Antona C
Clin Cancer Res; 2012 Aug; 18(16):4441-8. PubMed ID: 22718863
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
[TBL] [Abstract][Full Text] [Related]
5. Yin yang 1 modulates taxane response in epithelial ovarian cancer.
Matsumura N; Huang Z; Baba T; Lee PS; Barnett JC; Mori S; Chang JT; Kuo WL; Gusberg AH; Whitaker RS; Gray JW; Fujii S; Berchuck A; Murphy SK
Mol Cancer Res; 2009 Feb; 7(2):210-20. PubMed ID: 19208743
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
Tokuda E; Seino Y; Arakawa A; Saito M; Kasumi F; Hayashi S; Yamaguchi Y
Breast Cancer Res Treat; 2012 Jun; 133(2):427-36. PubMed ID: 21909982
[TBL] [Abstract][Full Text] [Related]
7. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers.
Sale S; Sung R; Shen P; Yu K; Wang Y; Duran GE; Kim JH; Fojo T; Oefner PJ; Sikic BI
Mol Cancer Ther; 2002 Jan; 1(3):215-25. PubMed ID: 12467216
[TBL] [Abstract][Full Text] [Related]
8. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
Wheeler HE; Gamazon ER; Wing C; Njiaju UO; Njoku C; Baldwin RM; Owzar K; Jiang C; Watson D; Shterev I; Kubo M; Zembutsu H; Winer EP; Hudis CA; Shulman LN; Nakamura Y; Ratain MJ; Kroetz DL; ; Cox NJ; Dolan ME
Clin Cancer Res; 2013 Jan; 19(2):491-9. PubMed ID: 23204130
[TBL] [Abstract][Full Text] [Related]
9. Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy.
Stark AL; Hause RJ; Gorsic LK; Antao NN; Wong SS; Chung SH; Gill DF; Im HK; Myers JL; White KP; Jones RB; Dolan ME
PLoS Genet; 2014 Apr; 10(4):e1004192. PubMed ID: 24699359
[TBL] [Abstract][Full Text] [Related]
10. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers.
Komatsu M; Hiyama K; Tanimoto K; Yunokawa M; Otani K; Ohtaki M; Hiyama E; Kigawa J; Ohwada M; Suzuki M; Nagai N; Kudo Y; Nishiyama M
Mol Cancer Ther; 2006 Mar; 5(3):767-75. PubMed ID: 16546992
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
12. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
[TBL] [Abstract][Full Text] [Related]
13. Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.
Covell DG
PLoS One; 2012; 7(10):e44631. PubMed ID: 23056181
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of response to neoadjuvant paclitaxel treatment for locally advanced breast cancer.
Perez-Ortiz AC; Ramírez I; Cruz-López JC; Villarreal-Garza C; Luna-Angulo A; Lira-Romero E; Jiménez-Chaidez S; Díaz-Chávez J; Matus-Santos JA; Sánchez-Chapul L; Mendoza-Lorenzo P; Estrada-Mena FJ
Oncotarget; 2017 Dec; 8(63):106454-106467. PubMed ID: 29290962
[TBL] [Abstract][Full Text] [Related]
15. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.
O'Brien C; Cavet G; Pandita A; Hu X; Haydu L; Mohan S; Toy K; Rivers CS; Modrusan Z; Amler LC; Lackner MR
Cancer Res; 2008 Jul; 68(13):5380-9. PubMed ID: 18593940
[TBL] [Abstract][Full Text] [Related]
16.
Pu J; Shen J; Zhong Z; Yanling M; Gao J
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):639-647. PubMed ID: 32064933
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.
Giannakakou P; Sackett DL; Kang YK; Zhan Z; Buters JT; Fojo T; Poruchynsky MS
J Biol Chem; 1997 Jul; 272(27):17118-25. PubMed ID: 9202030
[TBL] [Abstract][Full Text] [Related]
18. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.
Bauer JA; Ye F; Marshall CB; Lehmann BD; Pendleton CS; Shyr Y; Arteaga CL; Pietenpol JA
Breast Cancer Res; 2010; 12(3):R41. PubMed ID: 20576088
[TBL] [Abstract][Full Text] [Related]
19. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
20. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
